NeoGenomics Q2 revenue up 11% to $202M; raises FY2026 guidance; settles DOJ matter

NEOGENOMICS INC

Total revenue $202M (+11% YoY); clinical revenue $187M (+14%); NGS revenue +26%.
GAAP net income $2M (incl. $11M debt extinguishment gain) vs net loss $45M in Q2 2025.
Adjusted EBITDA $14M (+36% YoY); company raises full-year 2026 revenue and adjusted EBITDA guidance.
Completed $316M 0.75% convertible notes due 2032; repurchased $276M of existing 0.25% notes and $25M of common stock.
Finalized civil settlement with DOJ regarding consulting services; self-disclosed matter resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.